Commentary|Slideshows|November 15, 2024

Risk Factors for Type 1 Diabetes: A Snapshot for Primary Care

About 40% of people who have T1D are not aware of it until they experience an extreme health event; screening in primary care can help reduce the risk, support families.

Routine screening for type 1 diabetes in the general population is not currently recommended due to its relatively low prevalence. However, screening is strongly advised for high-risk populations—those with a family history of T1D or certain genetic markers associated with increased risk.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Latest CME

$(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee$

Risk Factors for Type 1 Diabetes: A Snapshot for Primary Care

Related Content

Primary Care Lens: What HR 1 Means for Medicaid and Primary Care

FDA Approves Mucinex 12HR Cold & Fever, First New OTC Cold and Flu NDA in 14 Years

Centanafadine Gains FDA Approval for ADHD Across Age Groups

New CVD Risk Model Flags Heart Disease Earlier in Reproductive-Age Women

5 FDA Decisions for Primary Care to Know from July 2026

Latest CME

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Tennessee

Empire State Hematology & Oncology Society (New York)

South Carolina Oncology Society

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Washington

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Montana/Wyoming

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – North Carolina

Une Vision d’Espoir: Lighting the Way in GA Management & Treatment

Breaking Down the Rationale for Targeting TROP2 in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Arizona

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Show Me Your Care Plan™: Navigating Biomarkers to Guide and Support NSCLC Care

Kansas Society of Clinical Oncology

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Nevada

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

24th Annual International Congress on the Future of Breast Cancer® East

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Project ECHO®: Advancing Care in Metastatic TNBC Through PD-L1–Informed Novel Frontline ADC Strategies

25th Annual International Congress on the Future of Breast Cancer® West

25th Annual International Congress on the Future of Breast Cancer® East

Medical Crossfire®: BPDCN in 2026—Expert Perspectives on Diagnosis, Frontline Therapy, and the Evolving CD123-Directed Pipeline

Arizona Clinical Oncology Society

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Medical Crossfire®: Maximizing Durability Across Retinal Disease — What 3 Years of Evidence Means for Your Practice

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Houston Hematology Satellite Symposia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

Radioligand Therapy 101: The Science Behind the Strategy

AREDS3 and Beyond: The Scientific Basis for B Vitamin Nutritional Supplementation in AMD

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Wisconsin Association of Hematology and Oncology

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Colorado Oncology Society

Pathways to Progress: RAS in GI Cancers (Spotlight CE Session)

EyeCon 2026

27th Annual International Lung Cancer Congress®

Tackling Barriers to Vaccine Uptake: Practical Strategies for Adult Immunization

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Satellite Symposia at the Annual Radiation Oncology Meeting

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

Minnesota Society of Clinical Oncology

The Optometry Meeting in Anaheim

North Carolina Oncology Association

Jersey City Psychiatry

2026 International Symposium of Gastrointestinal Oncology (ISGIO)

26th Annual International Lung Cancer Congress